Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients

Journal of Clinical Psychopharmacology

Volumn 19, Issue 4, 1999, Pages 310-315

  Hesslinger, Bernd ^a   Normann, Claus ^a   Langosch, Jens M ^a   Klose, Patrick ^a   Berger, Mathias ^a   Walden, Joerg ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; CARBAMAZEPINE; CHLORPROTHIXENE; HALOPERIDOL; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; MALE; PRIORITY JOURNAL; SCHIZOIDISM; SCHIZOPHRENIA;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; CARBAMAZEPINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HALOPERIDOL; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VALPROIC ACID;

EID: 0032767148     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199908000-00005     Document Type: Article

References (46)

1. Baldessarini RJ, Kando JC, Centorrino F. Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. Am J Psychiatry 1995;152:1038-44.
2. Iwahashi K, Miyatake R, Suwaki H, Hosokawa K, Ichikawa Y. The drug-drug interaction effects of haloperidol on plasma carbamazepine levels. Clin Neuropharmacol 1995;18:233-6.
3. Pupeschi G, Aganat C, Levron JC, Barges-Bertocchio MH. Do enzyme inducers modify haloperidol decanoate rate of release? Prog Neuropsychopharmacol Biol Psychiatry 1994;18:1323-32.
4. Kahn EM, Schulz SC, Perel JM, Alexander JE. Change in haloperidol level due to carbamazepine: a complicating factor in combined medication for schizophrenia. J Clin Psychopharmacol 1990;10:54-7.
5. Jann MW, Ereshefsky L, Saklad SR, Seidel DR, Davis CM, Burch NR, Bowden CL. Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol 1985;5:106-9.
6. Kidron R, Averbuch I, Klein E, Belmaker RH. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol Psychiatry 1985;20:219-22.
7. Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Suzuki A, Furukori H, Kaneko S, Inoue Y. Interaction between carbamazepine and bromperidol. Eur J Clin Pharmacol 1997;52:219-22.
8. Neppe VM. Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. J Clin Psychiatry 1983;44:326-31.
9. Heh CW, Sramek J, Herrera J, Costa J. Exacerbation of psychosis after discontinuation of carbamazepine treatment. Am J Psychiatry 1988;145:878-9.
10. Sramek J, Herrera J, Costa J, Heh C, Tran-Johnson T, Simpson G. A carbamazepine trial in chronic, treatment-refractory schizophrenia. Am J Psychiatry 1988;145:748-50.
11. Jann MW, Fidone GS, Hernandez JM, Amrung S, Davis CM. Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation. Psychiatry Res 1989;28:153-9.
12. Arana GW, Goff DC, Friedman H, Ornsteen M, Greenblatt DJ, Black B, Shader RI. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am J Psychiatry 1986;143:650-1.
13. Fast DK, Jones BD, Kusalik M, Erickson M. Effect of carbamazepine on neuroleptic plasma level and efficacy. Am J Psychiatry 1986;143:117-8.
14. Dose M, Apelt S, Emrich HM. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Res 1987;22:303-10.
15. Martin Munoz JC, Morinigo Dominguez AV, Mateo Martin I, Guajardo-Fajardo Ibarra I, Noval Lamos D. Carbamazepine: an effective adjuvant treatment in schizophrenia. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1992;20:11-6.
16. Wetterling T. Open clinical trial of carbamazepine in chronic schizophrenic inpatients. Pharmacopsychiatry 1987;20:127-30.
17. Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol vs placebo and haloperidol in excited psychoses. Arch Gen Psychiatry 1984;41:165-71.
18. Okuma Y, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, Sarai K, Hazama H, Inanaga K. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand 1989;80:250-9.
19. Herrrera JM, Sramek JJ, Costa J. Efficacy of adjunctive carbamazepine in the treatment of chronic schizophrenia. Drug Intell Clin Pharm 1987;21:355-8.
20. Nachshoni T, Levin Y, Levy A, Kritz A, Neumann M. A double-blind trial of carbamazepine in negative symptom schizophrenia. Biol Psychiatry 1994;35:22-6.
21. Llorca PM, Wolf MA, Lancon C, Bougerol T. Comparative efficacy of bromocriptine, carbamazepine and cyproheptadine with neuroleptics in 24 refractory chronic schizophrenics. Encephale 1993;19:565-71.
22. Carpenter WT, Kurz R, Kirkpatrick B, Hanlon TE, Summerfelt AT, Buchanan R, Waltrip RW, Breier A. Carbamazepine maintenance treatment in outpatient schizophrenics. Arch Gen Psychiatry 1991;48:69-71.
23. McElroy SL, Keck PE, Hudson JI. Treatment of psychiatric disorders with valproate: a series of 73 cases. Psychiatr Psychobiol 1992;3:81-5.
24. Moringio A, Martin J, Gonzalez S, Mateo I. Treatment of resistant schizophrenia with valproate and neuroleptic drugs. Hillside J Clin Psychiatry 1989;11:199-207.
25. Altamura AC, Basile R, Mauri M, Cazzullo CL. Valpromide (Depamide) in the treatment of acute psychotic states. Acta Psychiatr Belg 1986;86:297-304.
26. Gardos G, Cole JO. A forgotten antipsychotic. Hosp Community Psychiatry 1990;41:1261-2.
27. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
28. Lorr M, Klett JC. Inpatient Multidimensional Psychiatric Scale (IMPS). Washington (DC): The Catholic University of America, 1979.
29. Hoffman DW, Edkins RD. Solid-phase extraction and high-performance liquid chromatography for therapeutic monitoring of haloperidol levels. Ther Drug Monit 1994;16:504-8.
30. Llerena A, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992;14:261-4.
31. Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol 1991;31:655-60.
32. Goff DC, Midha KK, Brotman AW, Waites M, Baldessarini RJ. Evaluation of plasma concentrations of haloperidol after the addition of fluoxetine. Am J Psychiatry 1991;148:790-2.
33. Fang J, Baker GB, Silverstone PH, Coutts RT. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 1997;17:227-33.
34. Usuki E, Pearce R, Parkinson A, Castagnol N Jr. Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes. Chemical Res Toxicol 1996;9:800-6.
35. Pan LP, Wijnant P, De Vriendt C, Rosseel MT, Belpaire FM. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. Br J Clin Pharmacol 1997;44:557-64.
36. Ketter TA, Post RM, Worthington K. Principles of clinically important drug interactions with carbamazepine, parts 1 and 2. J Clin Psychopharmacol 1991;11:198-203, 306-13.
37. Leinonen E, Lillsunde P, Laukkanen V, Ylitalo P. Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. J Clin Psychopharmacol 1991;11:313-8.
38. Lai AA, Levy RH, Cutler RE. Time-course of interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther 1978;24:316-23.
39. Leinonen E, Lillsunde P, Laukkanen V, Ylitalo P. Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. J Clin Psychopharmacol 1991;11:313-8.
40. Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E. The effect of carbaniazepine on the 2-hydroxylation of desipramine. Psychopharmacology (Berl) 1995;117:413-6.
41. Otani K, Ishida M, Mihara K, Ohkubo T, Osanai T, Sugawara K. Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine. Ther Drug Monit 1996;18:164-7.
42. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 1995;28:26-8.
43. Van Putten T, Marder SR, Mintz J, Poland RE. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 1992;149:500-5.
44. Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid - 1988. Clin Pharmacokinet 1988;15:367-89.
45. Bourgeois BFD. Pharmacologic interactions between valproate and other drugs. Am J Med 1988;84:29-33.
46. Wong SL, Cavanaugh J, Shi H, Awni WM, Granneman GR. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther 1996;60:48-53.